CAJ | 학술논문

钠-葡萄糖共转运蛋白2（SGLT2）抑制剂是一类新兴的治疗糖尿病的药物。近年来，遗传学和药理学研究发现，胃肠道SGLT1蛋白也可能成为一个有治疗前景的药物靶点。SGLT1/SGLT2双靶点抑制剂的开发将为糖尿病的治疗提供另一个非胰岛素依赖的途径。临床研究表明，sotagliflozin可以通过双重抑制SGLT1和SGLT2的作用来降低餐后血糖、升高GLP-1和促进尿糖排出。因此，这些特征使得sotagliflozin在对1型和2型糖尿病的治疗方面具有重要临床意义。
납-포도당공전운단백2（SGLT2）억제제시일류신흥적치료당뇨병적약물。근년래，유전학화약이학연구발현，위장도SGLT1단백야가능성위일개유치료전경적약물파점。SGLT1/SGLT2쌍파점억제제적개발장위당뇨병적치료제공령일개비이도소의뢰적도경。림상연구표명，sotagliflozin가이통과쌍중억제SGLT1화SGLT2적작용래강저찬후혈당、승고GLP-1화촉진뇨당배출。인차，저사특정사득sotagliflozin재대1형화2형당뇨병적치료방면구유중요림상의의。
The sodium-dependent glucose transporter 2 (SGLT2) inhibitors is an important emerging class for the treatment of diabetes. In recent years, genetic and pharmacology researches have indicated that gastrointestinal SGLT1 inhibitors may also be an appropriate therapeutic target to treat diabetes. Combining SGLT1 and SGLT2 inhibitors in a single molecule would provide complementary insulin-independent mechanisms to treat diabetes. Therefore, sotagliflozin has been developed as a dual inhibitor of SGLT1 and SGLT2. The differentiating clinical features of dual inhibitor of SGLT1 and SGLT2 include a large postprandial glucose reduction, elevation of glucagon-like peptide 1 and modest urinary glucose excretion. These features may have clinical implications for the use of sotagliflozin in the treatment of both type 1 and type 2 diabetes.